Exercise or conversion
Fady Ibraham Malik
EVP Research & Development
Common Stock
- Value context
- $27.3K
- Reported price
- $7.80 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
CYTOKINETICS INC
Last 30 daysNo qualifying insider buying. Sales: $8.7M by 3 insiders.
Showing the first 6 of 20 trades on this page.
EVP Research & Development
Common Stock
EVP Research & Development
Non-Qualified Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & CEO
Common Stock
President & CEO
Non-Qualified Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
EVP Research & Development
Common Stock
EVP Research & Development
Non-Qualified Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & CEO
Common Stock
President & CEO
Common Stock
The filing reports a zero transaction price for this gift. It does not establish the market value of the gift.
President & CEO
Common Stock
The filing reports a zero transaction price for this gift. It does not establish the market value of the gift.
President & CEO
Common Stock
The filing reports a zero transaction price for this gift. It does not establish the market value of the gift.
President & CEO
Non-Qualified Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
EVP Research & Development
Common Stock
EVP Research & Development
Non-Qualified Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
EVP, Chief Commercial Officer
Common Stock
EVP, Chief Commercial Officer
Non-Qualified Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & CEO
Common Stock
President & CEO
Non-Qualified Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
EVP Research & Development
Common Stock
EVP Research & Development
Non-Qualified Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
President & CEO
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| EVP Research & Development | Common StockOption exercise or conversion10b5-1 | 3,500$7.80 / share | $27.3K | Oct 6Filed Oct 6 · 0d later | SEC filing |
| EVP Research & Development | Non-Qualified Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units3,500$7.80 exercise / conversion price | Not a separate purchase | Oct 6Filed Oct 6 · 0d later | SEC filing |
| President & CEO | Common StockOption exercise or conversion10b5-1 | 7,500$10.60 / share | $79.5K | Sep 28Filed Sep 28 · 0d later | SEC filing |
| President & CEO | Non-Qualified Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units7,500$10.60 exercise / conversion price | Not a separate purchase | Sep 28Filed Sep 28 · 0d later | SEC filing |
| EVP Research & Development | Common StockOption exercise or conversion10b5-1 | 3,500$7.80 / share | $27.3K | Sep 22Filed Sep 22 · 0d later | SEC filing |
| EVP Research & Development | Non-Qualified Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units3,500$7.80 exercise / conversion price | Not a separate purchase | Sep 22Filed Sep 22 · 0d later | SEC filing |
| President & CEO | Common StockOption exercise or conversion10b5-1 | 7,500$10.60 / share | $79.5K | Sep 14Filed Sep 15 · 1d later | SEC filing |
| President & CEO | Common StockGift10b5-1 | 1,350Gift · no purchase price | Not a purchase | Sep 14Filed Sep 15 · 1d later | SEC filing |
| President & CEO | Common StockGift10b5-1 | 97,926Gift · no purchase price | Not a purchase | Sep 14Filed Sep 15 · 1d later | SEC filing |
| President & CEO | Common StockGift10b5-1 | 97,926Gift · no purchase price | Not a purchase | Sep 14Filed Sep 15 · 1d later | SEC filing |
| President & CEO | Non-Qualified Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units7,500$10.60 exercise / conversion price | Not a separate purchase | Sep 14Filed Sep 15 · 1d later | SEC filing |
| EVP Research & Development | Common StockOption exercise or conversion10b5-1 | 3,500$7.80 / share | $27.3K | Sep 8Filed Sep 8 · 0d later | SEC filing |
| EVP Research & Development | Non-Qualified Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units3,500$7.80 exercise / conversion price | Not a separate purchase | Sep 8Filed Sep 8 · 0d later | SEC filing |
| EVP, Chief Commercial Officer | Common StockOption exercise or conversion10b5-1 | 10,000$23.26 / share | $232.6K | Aug 31Filed Aug 31 · 0d later | SEC filing |
| EVP, Chief Commercial Officer | Non-Qualified Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units10,000$23.26 exercise / conversion price | Not a separate purchase | Aug 31Filed Aug 31 · 0d later | SEC filing |
| President & CEO | Common StockOption exercise or conversion10b5-1 | 7,500$10.60 / share | $79.5K | Aug 31Filed Aug 31 · 0d later | SEC filing |
| President & CEO | Non-Qualified Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units7,500$10.60 exercise / conversion price | Not a separate purchase | Aug 31Filed Aug 31 · 0d later | SEC filing |
| EVP Research & Development | Common StockOption exercise or conversion10b5-1 | 3,500$7.80 / share | $27.3K | Aug 18Filed Aug 18 · 0d later | SEC filing |
| EVP Research & Development | Non-Qualified Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units3,500$7.80 exercise / conversion price | Not a separate purchase | Aug 18Filed Aug 18 · 0d later | SEC filing |
| President & CEO | Common StockOption exercise or conversion10b5-1 | 7,500$10.60 / share | $79.5K | Aug 10Filed Aug 10 · 0d later | SEC filing |
Showing the latest 20 of 115 trades. Show all 115 trades
No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
Cytokinetics, Incorporated - Common Stock (CYTK) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberCytokinetics, Incorporated - Common Stock (CYTK) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House member